

Hospital Pharmaceuticals Review
PTAC and Hospital Pharmaceuticals Subcommittee minutes for
web publishing

Various therapeutic group

PTAC and Subcommittee of PTAC minutes are published in accordance with the *Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008*.

This document contains minutes relevant to the consultation document of 25 February 2013 relating to products in the Various therapeutic group.

Note that this document is not a complete record of the relevant PTAC and Subcommittee meetings; only the relevant portions of the minutes relating PTAC and its Subcommittees advice on the review of Hospital Pharmaceuticals are included.

Contents

Hospital Pharmaceuticals Subcommittee – 3 April 2012	2
Hospital Pharmaceuticals Subcommittee – 11 December 2012	7
Pharmacology and Therapeutics Advisory Committee – 14 & 15 February 2013	8

Hospital Pharmaceuticals Subcommittee – 3 April 2012

1 Agents Used in the Treatment of Poisonings

- 1.1 The Subcommittee reviewed the information from DHB hospitals and PHARMAC in relation to products under the Agents Used in the Treatment of Poisonings heading.
- 1.2 The Subcommittee noted that the following pharmaceuticals are commonly used in DHB hospitals and/or are fully subsidised in the Pharmaceutical Schedule and recommended that they be included in a national preferred medicines list (PML) without need for further prioritisation:
 - Acetylcysteine
 - Inj 200 mg per ml, 10 ml
 - Inj 200 mg per ml, 30 ml
 - Tab eff 200 mg
 - Ethanol, dehydrated
 - Inf 100%, 5 ml
 - Flumazenil
 - Inj 0.1 mg per ml, 5 ml
 - Naloxone hydrochloride
 - Inj 400 µg per ml, 1 ml
 - Pralidoxime iodide
 - Inj 25 mg per ml, 20 ml
 - Sodium nitrite
 - Inj 30 mg per ml, 10 ml
 - Sodium thiosulfate
 - Inj 250 mg per ml, 10 ml
 - Red back spider antivenom
 - Inj 500 u
 - Charcoal
 - Oral liq 50 g per 250 ml
 - Deferiprone
 - Oral liq 100 mg per ml
 - Tab 500 mg
 - Desferrioxamine mesylate
 - Inj 500 mg
 - Dicobalt edentate
 - Inj 15 mg per ml, 20 ml
 - Dimercaprol
 - Inj 50 mg per ml, 2 ml
- 1.3 Members noted that digoxin immune Fab injection 38 mg (Digibind) has been widely used in DHB hospitals, but that it has been discontinued. The Subcommittee recommended that the 40 mg injection (DigiFab) be included in a national PML.
- 1.4 Members noted that DHB hospitals are currently using a 500 mg per ml strength of sodium thiosulfate due to an out of stock event, and that this may become a permanent switch.

1.5 The Subcommittee noted that the following pharmaceuticals are not subsidised in the community and are not widely used in DHB hospitals, but recommended that they be included in a national PML:

- Ethanol with glucose
 - Inf 10% with glucose 5%, 500 ml
- Glucarpidase (carboxypeptidase G2)
 - Inj 1000 u
- Diphtheria antitoxin
 - Inj 10,000 iu
- Snake antivenom
 - Inj
- Charcoal
 - Tab 300 mg
- Dimercaptosuccinic acid
 - Cap 100 mg
- Disodium edentate
 - Inj 150 mg per ml, 100 ml
 - Inj 150 mg per ml, 20 ml amp
 - Inj 150 mg per ml, 20 ml vial
- Sodium calcium edentate
 - Inj 200 mg per ml, 2.5 ml
 - Inj 200 mg per ml, 5 ml

1.6 The Subcommittee noted that botulism antitoxin 250 ml injection is held at Auckland DHB on behalf of the Ministry of Health, and recommended that this be included in a national PML.

1.7 The Subcommittee note the following pharmaceuticals are not subsidised in the Pharmaceutical Schedule and are not widely used in DHB hospitals, and recommended that they not be included in a national PML:

- Acetylcysteine
 - Tab eff 600 mg
- Ethanol
 - Liq 96%
- Ethanol, dehydrated
 - Inf 100%, 20 ml
- Ipecacuanha
 - Tincture
- Naloxone hydrochloride
 - Inj 400 µg per ml, 2 ml pre-filled syringe
- Deferasirox
 - Tab 125 mg
 - Tab 250 mg
 - Tab 500 mg
- Fuller's earth
 - Powder

1.7.1 The Subcommittee recommended that the view of the National Poisons Centre be sought on the need for fuller's earth in DHB hospitals.

2 Contrast Media

- 2.1 The Subcommittee reviewed the information from DHB hospitals and PHARMAC in relation to products under the Contrast Media heading.
- 2.2 The Subcommittee noted that there is a wide range of products available for MRI contrast and radio contrast media, and that on the available information there appears to be significant variability in the use of these products within DHB hospitals.
- 2.3 The Subcommittee recommended seeking the advice of radiologists as to the products that would be necessary to have included in a national PML, and as to whether there is scope for standardisation across DHB hospitals.

3 Diagnostic Agents

- 3.1 The Subcommittee reviewed the information from DHB hospitals and PHARMAC in relation to products under the Diagnostic Agents heading.
- 3.2 The Subcommittee noted that most of these agents are not widely used in DHB hospitals, but recommended that the following be included in a national PML:
 - Arginine
 - Inf 5%
 - Inf 10%
 - Inf 600 mg per ml, 1 ml
 - Corticorelin
 - Inj 100 µg
 - Histamine acid phosphate
 - Nebuliser soln 0.6%, 10 ml vial
 - Nebuliser soln 2.5%, 10 ml vial
 - Nebuliser soln 5%, 10 ml vial
 - Secretin pentahydrochloride
 - Inj 100 u
 - Tuberculin, purified protein derivative
 - Inj 10 TIU per 0.1 ml, 1 ml
 - Fluorescein sodium
 - Inj 10%, 5 ml
 - Indigo carmine
 - Inj 4 mg per ml, 5 ml
 - Inj 8 mg per ml, 5 ml
 - Indocyanine green
 - Inj 25 mg
 - Methylthioninium chloride trihydrate
 - Inj 10 mg per ml, 5 ml
 - Inj 10 mg per ml, 10 ml
 - Patent blue V
 - Inj 2.5%, 2 ml
- 3.3 The Subcommittee noted that sincalide (inj 5 µg) is not widely used in DHB hospitals, and that it is difficult to obtain stock of this product. The Subcommittee recommended that it not be included in a national PML, but recommended that PHARMAC consult with paediatric gastroenterologists on its potential exclusion.

- 3.4 The Subcommittee noted that there is some use of Bonney's blue dye in DHB hospitals, but noted that this use is not as a diagnostic agent, and therefore should not be included in a national PML.
- 3.5 The Subcommittee recommended seeking advice from clinical immunologists on which allergy testing kits should be included in a national PML.

4 Irrigation Solutions

- 4.1 The Subcommittee reviewed the information from DHB hospitals and PHARMAC in relation to products under the Irrigation Solutions heading.
- 4.2 The Subcommittee noted that DHBs had not reported significant use of irrigation solutions, but recommended that the following be included in a national PML:
- Chlorhexidine
 - Irrigation soln 0.1%, 30 ml
 - Irrigation soln 0.02%, 100 ml
 - Irrigation soln 0.02%, 500 ml
 - Irrigation soln 0.05%, 100 ml
 - Irrigation soln 0.05%, 500 ml
 - Irrigation soln 0.1%, 100 ml
 - Irrigation soln 0.5%, 500 ml
 - Chlorhexidine with cetrimide
 - Irrigation soln 0.015% with cetrimide 0.15%, 30 ml
 - Irrigation soln 0.015% with cetrimide 0.15%, 100 ml
 - Irrigation soln 0.015% with cetrimide 0.15%, 500 ml
 - Irrigation soln 0.015% with cetrimide 0.15%, 1000 ml
 - Irrigation soln 0.05% with cetrimide 0.5%, 100 ml
 - Irrigation soln 0.05% with cetrimide 0.5%, 500 ml
 - Irrigation soln 0.1% with cetrimide 1%, 100 ml
 - Irrigation soln 0.1% with cetrimide 1%, 500 ml
 - Glycine
 - Irrigation soln 1.5%, 2000 ml
 - Irrigation soln 1.5%, 3000 ml
 - Sodium chloride
 - Irrigation soln 0.9%, 30 ml
 - Irrigation soln 0.9%, 100 ml
 - Irrigation soln 0.9%, 500 ml
 - Irrigation soln 0.9%, 1000 ml
 - Irrigation soln 0.9%, 2,000 ml
 - Irrigation soln 0.9%, 3,000 ml
 - Water
 - Irrigation soln, 100 ml
 - Irrigation soln, 500 ml
 - Irrigation soln, 1000 ml
 - Irrigation soln, 2000 ml

5 Surgical Preparations

- 5.1 The Subcommittee reviewed the information from DHB hospitals and PHARMAC in relation to products under the Surgical Preparations heading.
- 5.2 The Subcommittee noted that DHBs had not reported significant use of these products, but recommended that the following be included in a national PML:
- Bismuth subnitrate and iodoform paraffin
 - Paste
 - Dimethyl sulfoxide
 - Soln 50%
 - Phenol
 - Inj 6%, 10 ml
 - Trometamol
 - Inf 18 g per 500 ml
 - Citric acid with monosodium aspartate, monosodium glutamate, sodium acid phosphate, sodium citrate and trometamol
 - Soln
 - Citric acid with potassium chloride, sodium citrate, sodium phosphate and trometamol
 - Soln
 - Dextran 40 with glucose, magnesium, phosphate and potassium
 - Soln 5% with glucose 5mmol/L, magnesium 0.8 mmol/L, phosphate 0.8 mmol/L and potassium 6 mmol/L, 2,800 ml
 - Magnesium chloride with potassium chloride and procaine hydrochloride
 - Soln 80 mmol/L with potassium chloride 80 mmol/L and procaine hydrochloride 5 mmol/L, 20 ml
- 5.3 The Subcommittee noted that calcium chloride dihydrate 0.17 mg with magnesium chloride hexahydrate 3.25 mg, potassium chloride 1.19 mg and sodium chloride 6.43 mg per ml solution had been discontinued, and considered that this did not need to be included in a national PML.

Hospital Pharmaceuticals Subcommittee – 11 December 2012

6 Review of Various Recommendations

- 6.1 The Subcommittee reviewed its previous recommendations in relation to products in the Various group and feedback from other organisations.

Diagnostic Agents

- 6.2 The Subcommittee noted that it had previously recommended against including Bonny's blue dye in a national PML. The Subcommittee recommended that it be included, as it is used surgery for skin marking.

Pharmacology and Therapeutics Advisory Committee – 14 & 15 February 2013

7 Hospital Pharmaceuticals Review

- 7.1 The Committee considered a list of pharmaceuticals under consideration for use in DHB hospitals under the Various heading, including advice from the Hospital Pharmaceuticals Subcommittee. The Committee agreed with the recommendations by the subcommittee.